996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14
Frank P. Y. Lin, M. Itchins, S. Chinchen, Subotheni Thavaneswaran et autres
au (code pays fourni par la source)